Page 94 - ITPS-8-1

INNOSC Theranostics and
Pharmacological Sciences Brain glutamate level after treatment with NAC

doi: 10.32598/bcn.2022.1604.3 disorder: Insights into neural circuitry dysfunction through
mouse genetics. Curr Opin Neurobiol. 2011;21(6):842-848.
23. Eissazade N, Mosavari H, Eghdami S, Boroon M,
Ashrafi F, Shalbafan M. Efficacy and safety of doi: 10.1016/j.conb.2011.04.010
5-hydroxytryptamine-3 (5-HT3) receptor antagonists in 33. Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S,
augmentation with selective serotonin reuptake inhibitors Shalbafan M. Glutamatergic medications as adjunctive
(SSRIs) in the treatment of moderate to severe obsessive- therapy for moderate to severe obsessive-compulsive
compulsive disorder: A systematic review and meta-analysis disorder in adults: A systematic review and meta-analysis.
of randomized clinical trials. Sci Rep. 2023;13(1):20837. BMC Pharmacol Toxicol. 2021;22(1):69.
doi: 10.1038/s41598-023-47931-x doi: 10.1186/s40360-021-00534-6
24. Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, 34. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of
Shalbafan M. Memantine augmentation of sertraline in glutamate signaling in the pathogenesis and treatment of
the treatment of symptoms and executive function among obsessive-compulsive disorder. Pharmacol Biochem Behav.
patients with obsessive-compulsive disorder: A double- 2012;100(4):726-735.
blind placebo-controlled, randomized clinical trial. BMC
Psychiatry. 2022;22(1):34. doi: 10.1016/j.pbb.2011.10.007
doi: 10.1186/s12888-021-03642-z 35. Pittenger C, Bloch MH, Williams K. Glutamate
abnormalities in obsessive compulsive disorder:
25. Shalbafan M, Malekpour F, Tadayon Najafabadi B, Neurobiology, pathophysiology, and treatment. Pharmacol
et al. Fluvoxamine combination therapy with tropisetron Ther. 2011;132(3):314-332.
for obsessive-compulsive disorder patients: A placebo-
controlled, randomized clinical trial. J Psychopharmacol. doi: 10.1016/j.pharmthera.2011.09.006
2019;33(11):1407-1414. 36. Ting JT, Feng G. Glutamatergic synaptic dysfunction and
doi: 10.1177/0269881119878177 obsessive-compulsive disorder. Curr Chem Genomics.
2008;2:62-75.
26. Van Noppen BL, Pato MT, Marsland R, Rasmussen SA. A time-
limited behavioral group for treatment of obsessive-compulsive doi: 10.2174/1875397300802010062
disorder. J Psychother Pract Res. 1998;7(4):272-280. 37. Chakrabarty K, Bhattacharyya S, Christopher R,
27. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Khanna S. Glutamatergic dysfunction in OCD.
Combination treatment with clomipramine and selective Neuropsychopharmacology. 2005;30(9):1735-1740.
serotonin reuptake inhibitors for obsessive-compulsive doi: 10.1038/sj.npp.1300733
disorder in children and adolescents. J Child Adolesc
Psychopharmacol. 1998;8(1):61-67. 38. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD,
Stewart CM, Moore GJ. Decrease in caudate glutamatergic
doi: 10.1089/cap.1998.8.61 concentrations in pediatric obsessive-compulsive disorder
28. Treatment of obsessive-compulsive disorder. The expert patients taking paroxetine. J Am Acad Child Adolesc
consensus panel for obsessive-compulsive disorder. J Clin Psychiatry. 2000;39(9):1096-1103.
Psychiatry. 1997;58(Suppl 4):2-72. doi: 10.1097/00004583-200009000-00008
29. Decloedt EH, Stein DJ. Current trends in drug treatment 39. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A,
of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. Christopher R, Shankar SK. Anti-brain autoantibodies and
2010;6:233-242. altered excitatory neurotransmitters in obsessive-compulsive
disorder. Neuropsychopharmacology. 2009;34(12):2489-2496.
doi: 10.2147/ndt.s3149
doi: 10.1038/npp.2009.77
30. Marinova Z, Chuang DM, Fineberg N. Glutamate-
modulating drugs as a potential therapeutic strategy in 40. Ozdemir E, Cetinkaya S, Ersan S, Kucukosman S, Ersan EE.
obsessive-compulsive disorder. Curr Neuropharmacol. Serum selenium and plasma malondialdehyde levels and
2017;15(7):977-995. antioxidant enzyme activities in patients with obsessive-
compulsive disorder. Prog Neuropsychopharmacol Biol
doi: 10.2174/1570159X15666170320104237
Psychiatry. 2009;33(1):62-65.
31. Zhu Y, Fan Q, Han X, et al. Decreased thalamic glutamate doi: 10.1016/j.pnpbp.2008.10.004
level in unmedicated adult obsessive-compulsive
disorder patients detected by proton magnetic resonance 41. Ersan S, Bakir S, Erdal Ersan E, Dogan O. Examination
spectroscopy. J Affect Disord. 2015;178:193-200. of free radical metabolism and antioxidant defence
system elements in patients with obsessive-compulsive
doi: 10.1016/j.jad.2015.03.008
disorder. Prog Neuropsychopharmacol Biol Psychiatry.
32. Ting JT, Feng G. Neurobiology of obsessive-compulsive 2006;30(6):1039-1042.

Volume 8 Issue 1 (2025) 88 doi: 10.36922/itps.4887